Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE an… (NCT04224636) | Clinical Trial Compass
RecruitingPhase 2
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
Germany106 participantsStarted 2020-06-10
Plain-language summary
Aim of the study is to evaluate the efficacy of up-front atezolizumab/ bevacizumab (Atezo/Bev) followed by on-demand selective transarterial chemoembolization (sdTACE) and of initial synchronous treatment with TACE and Atezo/Bev in the treatment of unresectable HCC patients.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient's signed informed consent
✓. Age ≥18 years at time of signing Informed Consent Form
✓. Ability to comply with the study protocol, according to investigator's judgement
✓. Life expectancy of at least 12 weeks
✓. HCC with histologically confirmed diagnosis
✓. Disease that is not amenable to curative surgical and/or local ablation but eligible for TACE
✓. ECOG Performance Status of 0 or 1
✓. Child-Pugh class A or B7
Exclusion criteria
✕. Diffuse HCC or presence of vascular invasion or extrahepatic spread or more than 7 lesions or at least one lesion \>= 7 cm
✕. Clinically relevant ascites
✕. Uncontrolled pleural effusion or pericardial effusion
✕. History or presence of hepatic encephalopathy